Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other Conditions: Comparison of Epidemiological and Therapeutic Aspects with Deferoxamine

By Kontoghiorghes G.J.   Neocleous K.   Kolnagou A.  

Drug Safety, Vol. 26, Iss. 8, 2003-01 ,pp. : 553-584

Adis International

Access to resources Recommend Favorite

Deferiprone/deferoxamine overdose: ECG abnormalities and arrhythmias (first report with deferiprone): case report

By  

Reactions Weekly, Vol. 1, Iss. 1184, 2008-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Pharmacokinetics of Deferiprone in Patients with β-Thalassaemia: Impact of Splenectomy and Iron Status

By >  

Clinical Pharmacokinetics, Vol. 50, Iss. 1, 2011-01 ,pp. : 41-50

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Once-Daily Oral Chelation Therapy with Deferasirox versus Infusional Deferoxamine in Transfusion-Dependent Thalassaemia Patients: US Healthcare System Perspective

By Delea Thomas E.  

PharmacoEconomics, Vol. 25, Iss. 4, 2007-01 ,pp. : 329-342

Adis International

Access to resources Recommend Favorite

Advances in Iron Overload Therapies. Prospects for Effective Use of Deferiprone (L1), Deferoxamine, the New Experimental Chelators ICL670, GT56-252, L1NAll and their Combinations

By  

Current Medicinal Chemistry, Vol. 12, Iss. 23, 2005-11 ,pp. : 2663-2681

Bentham Science Publishers

Access to resources Recommend Favorite